Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Siemens Healthcare's Versant 440 molecular system

This article was originally published in Clinica

Executive Summary

Siemens Healthcare's Versant 440 molecular system has been awarded a supplementary PMA by the US FDA and may now be used in conjunction with the Versant HCV RNA 3.0 assay. The HCV RNA assay is used to manage the antiviral therapy given to hepatitis-C virus (HCV)-infected patients - interferon alfa-2b plus ribavirin. It measures HCV RNA levels at baseline and during treatment, and predicts the patients' virological response. The Versant 440 is a branched DNA system that bypasses nucleic acid extraction and reduces the risk of cross-contamination. It can integrate bar code data entry, automate reagent processing, perform signal amplification detection, and incorporates a Laboratory Information System which allows operators to download results. When run on the Versant 440, the HCV RNA 3.0 assay demonstrates "excellent precision across the entire reporting range and equivalent detection of all HCV RNA genotypes", Siemens claims. The Deerfield, Illinois firm CE marked the Versant 440 in September 2006, and has launched it throughout Europe, Africa, and parts of Asia and the Americas.

You may also be interested in...

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.

FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps

FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."

Power Of Proprietary Drug Names To Be Studied By US FDA

FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts